Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's a Cancer-Killing Stock to Buy for 2021

By Taylor Carmichael - Dec 30, 2020 at 7:18AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

"Natural killer" (or NK) cancer therapies are hot right now. Here are two stocks that are early leaders in the field -- one is a buy, and the other one is not.

In our bodies we have cancer-killer cells called "natural killer" cells, or NK cells. These cells are part of our innate immune system. When an NK cell comes across a malign cancer cell in the human body, the NK cell attacks it and destroys it. Scientists believe that this natural cancer-killer might unlock secrets to help us fight cancer.

Small, cutting-edge biotech companies want to harness these NK cells and grow them into effective cancer therapies. And in 2020 the market got rather excited about this scientific field. Shares of Fate Therapeutics ( FATE -0.33% ) ran up 374% in 2020, while NantKwest (NASDAQ:NK) jumped 262%. Here's why you should buy one stock, but probably not the other.

image of a target sight on a cancer cell

Image source: Getty Images.

The upside is high, but it's still very early

Fate Therapeutics is highly valued right now, with a market cap of $8 billion. The company has no drugs in pivotal trials yet. It has a large pipeline, but all its drugs are coming out of phase 1 trials. While there are some exciting things going on at Fate, that high a price tag for the company scares me off. The company's therapies are several years away from a possible approval from the Food and Drug Administration (FDA). Any number of discouraging things can happen on the way to the finish line. Investors are likely to find a cheaper price down the road.

The stock I bought is NantKwest. It's a lot cheaper than Fate, with a market cap of $1.4 billion. Like Fate, NantKwest is pursuing NK therapies, and it too has a large pipeline of drugs. A year ago the stock jumped 70% overnight after it presented at the J.P. Morgan Healthcare conference. The company had complete responses in multiple tumor types, including pancreatic cancer, triple negative breast cancer, and head and neck cancer. NantKwest actually has a head start on Fate, and has several drugs in phase 2 trials. So why is the company way behind in valuation? 

The perils of being too early

Several years ago, it was NantKwest that was receiving all the hype. NantKwest was founded by Dr. Patrick Soon-Shiong, the "richest doctor in the world" at the time. Soon-Shiong is a multi-billionaire entrepreneur who has made a lot of money selling cancer drugs in the past. This excited the bankers, and NantKwest had a $2.6 billion initial public offering (IPO), the largest ever for a biotech at the time. At a J.P. Morgan healthcare conference in 2016, Soon-Shiong announced "Moonshot 2020," and collaborations between his company and Amgen and Celgene.

Despite all this hype (or maybe because of it), the stock has been a disaster. Investors in the IPO are still under water. In retrospect, anyone buying this stock in 2015, without any human trials, was engaging in a whole lot of speculation. Shareholders immediately lost money. And the stock was dead money for years. 

Now, however, it's a different story. Investor interest is spiking again. But this time, that's because there is positive data in phase 1 and phase 2 human trials. To me, it appears that Soon-Shiong was right all along. Natural killer cells are indeed a very promising area of research. While the stock has not delivered (yet), the company is delivering (albeit later than promised). The 5-year chart tells us why the stock is so cheap, and the 1-year chart illustrates rising excitement over scientific results.  

NK Chart
Data source: YCharts

Mr. Market, who is very excited about Fate Therapeutics, might want to take another look at NantKwest. The company has been leading the way in NK research for a long time, and its pipeline is the most advanced, with several phase 2 trials ongoing.  

NK therapies plus a T-cell platform

Another thing that excited investors in 2020 is when Dr. Soon-Shiong announced a reverse merger of his public company NantKwest with his private one, ImmunityBio. His private company is focused on finding T-cell therapies from the adaptive immune system. And it has a bladder cancer drug, Anktiva, reporting fantastic data from a phase 2/phase 3 trial -- 72% of patients saw their tumors eliminated.

After the reverse merger is complete next year, NantKwest will be known as ImmunityBio and trade under the ticker IBRX. And in the second half of 2021, the company plans to file a new drug application with the FDA for Anktiva. 

So NantKwest investors have a wide-ranging platform of NK drugs that will increase in value as the market starts to appreciate the science. And investors should soon own the rights (post shareholder approval) to a breakthrough T-cell therapy for bladder cancer that's on the verge of filing for FDA approval.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NantKwest, Inc. Stock Quote
NantKwest, Inc.
Fate Therapeutics, Inc. Stock Quote
Fate Therapeutics, Inc.
$47.84 (-0.33%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.